JO3296B1 - مركبات فينوكسي إيثيل بيبريدين - Google Patents

مركبات فينوكسي إيثيل بيبريدين

Info

Publication number
JO3296B1
JO3296B1 JOP/2013/0177A JOP20130177A JO3296B1 JO 3296 B1 JO3296 B1 JO 3296B1 JO P20130177 A JOP20130177 A JO P20130177A JO 3296 B1 JO3296 B1 JO 3296B1
Authority
JO
Jordan
Prior art keywords
piperidine compounds
phenoxyethyl
phenoxyethyl piperidine
methyl
ethyl
Prior art date
Application number
JOP/2013/0177A
Other languages
English (en)
Inventor
Schulenburg York Jeremy
Allen Schiffler Matthew
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3296B1 publication Critical patent/JO3296B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

يتعلق الاختراع الحالي بتوفير مركب له الصيغة II: حيث يكون X عبارة عن: يكون R1 عبارة عن H، -CN، أو F؛ يكون R2 عبارة عن H أو ميثيل؛ يكون R3 عبارة عن H؛ و يكون R4 عبارة عن H، ميثيل، أو إيثيل؛ أو يكوِّن R3 وR4 المرتبطان معًا حلقة سايكلو بروبيل؛ أو ملحًا منه مقبولًا صيدليًا.
JOP/2013/0177A 2012-06-29 2013-06-13 مركبات فينوكسي إيثيل بيبريدين JO3296B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
JO3296B1 true JO3296B1 (ar) 2018-09-16

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0177A JO3296B1 (ar) 2012-06-29 2013-06-13 مركبات فينوكسي إيثيل بيبريدين

Country Status (43)

Country Link
US (2) US8962659B2 (ar)
EP (1) EP2867207B1 (ar)
JP (1) JP6127136B2 (ar)
KR (1) KR101653476B1 (ar)
CN (1) CN104411684B (ar)
AP (1) AP2014008164A0 (ar)
AR (1) AR091429A1 (ar)
AU (1) AU2013280875B2 (ar)
BR (1) BR112014031616B1 (ar)
CA (1) CA2875569C (ar)
CL (1) CL2014003535A1 (ar)
CO (1) CO7151507A2 (ar)
CR (1) CR20140553A (ar)
CY (1) CY1119425T1 (ar)
DK (1) DK2867207T3 (ar)
DO (1) DOP2014000287A (ar)
EA (1) EA024392B1 (ar)
EC (1) ECSP14033267A (ar)
ES (1) ES2644812T3 (ar)
GT (1) GT201400288A (ar)
HK (1) HK1203937A1 (ar)
HR (1) HRP20171515T1 (ar)
HU (1) HUE034425T2 (ar)
IL (1) IL236219A (ar)
JO (1) JO3296B1 (ar)
LT (1) LT2867207T (ar)
MA (1) MA37686B1 (ar)
ME (1) ME02840B (ar)
MX (1) MX345324B (ar)
MY (1) MY173878A (ar)
NZ (1) NZ701933A (ar)
PE (1) PE20150182A1 (ar)
PH (1) PH12015500009B1 (ar)
PL (1) PL2867207T3 (ar)
PT (1) PT2867207T (ar)
RS (1) RS56452B1 (ar)
SG (1) SG11201408641UA (ar)
SI (1) SI2867207T1 (ar)
TN (1) TN2014000501A1 (ar)
TW (1) TWI599561B (ar)
UA (1) UA114325C2 (ar)
WO (1) WO2014004229A1 (ar)
ZA (1) ZA201408632B (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
EP3083562B1 (en) * 2013-12-17 2017-09-27 Eli Lilly & Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
ES2894124T3 (es) 2017-05-18 2022-02-11 Idorsia Pharmaceuticals Ltd Derivados de indol N-sustituidos
ES2929309T3 (es) 2017-05-18 2022-11-28 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2
AR111874A1 (es) 2017-05-18 2019-08-28 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
PL3625222T3 (pl) 2017-05-18 2021-12-27 Idorsia Pharmaceuticals Ltd Pochodne fenylu jako modulatory receptora pge2
CN110612299A (zh) 2017-05-18 2019-12-24 爱杜西亚药品有限公司 作为pge2受体调节剂的嘧啶衍生物
US20220064113A1 (en) * 2019-01-22 2022-03-03 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
EP4245301A1 (en) 2020-11-13 2023-09-20 ONO Pharmaceutical Co., Ltd. Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
JP2005531516A (ja) * 2002-03-18 2005-10-20 ファイザー・プロダクツ・インク 選択的ｅｐ４受容体アゴニストによる治療方法
JP2006515015A (ja) * 2003-01-10 2006-05-18 エフ．ホフマン−ラ　ロシュ　アーゲー プロスタグランジンアゴニストとしての２−ピペリドン誘導体
OA13247A (en) * 2003-09-03 2007-01-31 Pfizer Phenyl or pyridyl amide coumpounds as prostaglandin E2 antagonists.
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
KR20070006891A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
WO2005105733A1 (en) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
US8598355B2 (en) 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
CA2789665C (en) 2010-02-22 2020-06-16 Raqualia Pharma Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
RU2606510C2 (ru) * 2010-09-21 2017-01-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция
EP2729141B1 (en) * 2011-07-04 2015-12-09 Rottapharm Biotech S.r.l. Cyclic amine derivatives as ep4 receptor agonists
JP5813223B2 (ja) * 2011-07-04 2015-11-17 ロッタファーム バイオテック エス アール エル Ｅｐ４レセプターアンタゴニストとしての環状アミン誘導体
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Also Published As

Publication number Publication date
BR112014031616B1 (pt) 2022-06-21
MX2014015953A (es) 2015-07-17
AU2013280875B2 (en) 2015-09-24
ZA201408632B (en) 2017-06-28
US20150126555A1 (en) 2015-05-07
IL236219A0 (en) 2015-02-01
PE20150182A1 (es) 2015-02-13
LT2867207T (lt) 2017-10-10
CL2014003535A1 (es) 2015-05-08
PL2867207T3 (pl) 2018-01-31
NZ701933A (en) 2017-01-27
DOP2014000287A (es) 2015-01-31
PT2867207T (pt) 2017-11-01
HK1203937A1 (en) 2015-11-06
PH12015500009A1 (en) 2015-03-02
PH12015500009B1 (en) 2015-03-02
CA2875569A1 (en) 2014-01-03
EP2867207A1 (en) 2015-05-06
ES2644812T3 (es) 2017-11-30
EA024392B1 (ru) 2016-09-30
UA114325C2 (uk) 2017-05-25
US9402838B2 (en) 2016-08-02
TWI599561B (zh) 2017-09-21
CA2875569C (en) 2016-04-19
KR20150013893A (ko) 2015-02-05
MA37686A1 (fr) 2016-09-30
TN2014000501A1 (en) 2016-03-30
WO2014004229A1 (en) 2014-01-03
ECSP14033267A (es) 2015-09-30
HUE034425T2 (en) 2018-02-28
AR091429A1 (es) 2015-02-04
MY173878A (en) 2020-02-26
CN104411684B (zh) 2016-08-24
DK2867207T3 (en) 2017-09-11
CN104411684A (zh) 2015-03-11
US20140005226A1 (en) 2014-01-02
MX345324B (es) 2017-01-25
SI2867207T1 (sl) 2017-10-30
US8962659B2 (en) 2015-02-24
CY1119425T1 (el) 2018-03-07
HRP20171515T1 (hr) 2017-11-17
EP2867207B1 (en) 2017-08-09
MA37686B1 (fr) 2017-04-28
RS56452B1 (sr) 2018-01-31
AP2014008164A0 (en) 2014-12-31
CR20140553A (es) 2015-02-04
TW201412717A (zh) 2014-04-01
SG11201408641UA (en) 2015-01-29
AU2013280875A1 (en) 2014-12-04
CO7151507A2 (es) 2014-12-29
JP6127136B2 (ja) 2017-05-10
IL236219A (en) 2017-12-31
BR112014031616A2 (pt) 2017-06-27
EA201492255A1 (ru) 2015-03-31
KR101653476B1 (ko) 2016-09-01
GT201400288A (es) 2015-08-27
JP2015522018A (ja) 2015-08-03
ME02840B (me) 2018-01-20

Similar Documents

Publication Publication Date Title
PH12015500009A1 (en) Phenoxyethyl piperidine compounds
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
MX2016006336A (es) Compuestos pirazolopirimidina.
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
MY165238A (en) Substituted pyrrolidine-2-carboxamides
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
JO3318B1 (ar) مثبطات bace
RS54730B1 (sr) Inhibitori beta sekretaze
MY172860A (en) Dimethyl-benzoic acid compounds
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX2015012629A (es) Compuestos de imidazo piridina.
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
MX364207B (es) Inhibidores de agrecanasa.
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
IN2014DN07996A (ar)
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
PH12015501056A1 (en) 2-pyridone compound
EA201690593A1 (ru) Новые соединения мочевины